Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial
These data suggest that 1L NALIRIFOX provides efficacy benefits for patients with mPDAC without compromising HRQoL or PS compared with Gem + NabP.
Authors
- Fawzi Benzaghou
- Roberto Pazo-Cid (ORCID: https://orcid.org/0000-0002-8026-7391)
- Andrew Scott Paulson (ORCID: https://orcid.org/0009-0000-6023-670X)
- Zev A. Wainberg (ORCID: https://orcid.org/0000-0002-7142-1246)
- E. Van Cutsem
- Davide Melisi (ORCID: https://orcid.org/0000-0002-4031-7585)
- Christelle de la Fouchardière (ORCID: https://orcid.org/0000-0003-2291-5693)
- T. Macarulla
- Fiona Maxwell (ORCID: https://orcid.org/0000-0002-0985-2870)
- Tanios Bekaii‐Saab (ORCID: https://orcid.org/0000-0001-7721-1699)
- Richard Hubner (ORCID: https://orcid.org/0000-0002-7081-8823)
- Thorsten Oliver Goetze (ORCID: https://orcid.org/0000-0002-8633-2748)
- Eileen Mary O'Reilly (ORCID: https://orcid.org/0000-0002-8076-9199)
- L. Zhang
- Shubham Pant (ORCID: https://orcid.org/0000-0001-9281-480X)
- Woo Jin Lee (ORCID: https://orcid.org/0000-0002-0549-464X)
- Sreenivasa R Chandana
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- Texas Oncology (US)
- Universitair Ziekenhuis Leuven (BE)
- Ipsen (United Kingdom) (GB)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Los Angeles Medical Center (US)
- Centre Léon Bérard (FR)
- Hospital Universitario Miguel Servet (ES)
- Masaryk Memorial Cancer Institute (CZ)
- National Cancer Center (KR)
- Mayo Clinic in Arizona (US)
- Vall d'Hebron Hospital Universitari (ES)
- The Christie NHS Foundation Trust (GB)
- Krankenhaus Nordwest (DE)
- Ipsen (United States) (US)
- Hematology Oncology Consultants (US)
- Vall d'Hebron Institute of Oncology (ES)
- KU Leuven (BE)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105534
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Ipsen Biopharmaceuticals
- Ipsen